Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial

CPX-351 (Europe: Vyxeos(®) liposomal; United States: Vyxeos(®)) is a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio. In a phase 3 study in older adults with newly diagnosed, high-risk/secondary AML, CPX-351 improved the remission frequency, overall...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortes, Jorge E., Lin, Tara L., Asubonteng, Kobby, Faderl, Stefan, Lancet, Jeffrey E., Prebet, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598030/
https://www.ncbi.nlm.nih.gov/pubmed/36289532
http://dx.doi.org/10.1186/s13045-022-01361-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598030/
https://www.ncbi.nlm.nih.gov/pubmed/36289532
http://dx.doi.org/10.1186/s13045-022-01361-w

Ejemplares similares